Jones Trading upgraded shares of Protara Therapeutics (NASDAQ:TARA - Free Report) to a strong-buy rating in a report issued on Thursday, Marketbeat Ratings reports. The brokerage currently has $21.00 price target on the stock.
TARA has been the subject of a number of other research reports. HC Wainwright restated a "buy" rating and set a $23.00 price objective on shares of Protara Therapeutics in a report on Monday, April 28th. Scotiabank assumed coverage on shares of Protara Therapeutics in a report on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 price objective for the company. Lifesci Capital started coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price target for the company. Finally, Cantor Fitzgerald began coverage on shares of Protara Therapeutics in a research note on Friday, March 14th. They issued an "overweight" rating for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $20.50.
View Our Latest Analysis on Protara Therapeutics
Protara Therapeutics Stock Performance
Shares of Protara Therapeutics stock traded up $0.07 on Thursday, reaching $3.20. 125,694 shares of the stock were exchanged, compared to its average volume of 770,427. The firm's 50 day moving average is $3.80 and its 200-day moving average is $4.17. Protara Therapeutics has a one year low of $1.60 and a one year high of $10.48. The firm has a market cap of $123.46 million, a PE ratio of -1.13 and a beta of 1.73.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.18. On average, equities research analysts expect that Protara Therapeutics will post -3.32 EPS for the current fiscal year.
Insider Buying and Selling at Protara Therapeutics
In related news, insider Jacqueline Zummo sold 21,224 shares of the company's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total value of $96,144.72. Following the completion of the sale, the insider now directly owns 98,861 shares of the company's stock, valued at $447,840.33. This represents a 17.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 8.40% of the company's stock.
Hedge Funds Weigh In On Protara Therapeutics
A number of large investors have recently added to or reduced their stakes in TARA. Walleye Capital LLC increased its holdings in Protara Therapeutics by 3.9% in the 1st quarter. Walleye Capital LLC now owns 229,454 shares of the company's stock worth $977,000 after buying an additional 8,640 shares during the period. Geode Capital Management LLC lifted its holdings in Protara Therapeutics by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock valued at $948,000 after purchasing an additional 9,553 shares in the last quarter. Charles Schwab Investment Management Inc. purchased a new position in Protara Therapeutics in the 1st quarter valued at $64,000. Commonwealth Equity Services LLC lifted its holdings in Protara Therapeutics by 90.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after purchasing an additional 17,572 shares in the last quarter. Finally, HBK Investments L P acquired a new stake in shares of Protara Therapeutics in the 4th quarter worth $106,000. 38.13% of the stock is currently owned by institutional investors.
Protara Therapeutics Company Profile
(
Get Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Read More
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
